Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Mark Stares"'
Autor:
Svenja Harvey, Mark Stares, Julie‐Anne Scott, Tharun Joseph Vattam Thottiyil, Alicia‐Marie Conway, Rachel Haigh, Jackie Brown, Gillian Knowles, Sonali Dasgupta, Kai‐Keen Shiu, Claire Mitchell, Colin Barrie, Natalie Cook, Sally Clive
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract Background Biomarkers of systemic inflammation have been shown to predict outcomes in patients with cancer of unknown primary (CUP). We sought to validate these findings in patients with confirmed CUP (cCUP) and explore their role alongside
Externí odkaz:
https://doaj.org/article/c5055b489f1a43e8828eba5e72f48749
Autor:
Samantha Su Ping Low, Karim El-Shakankery, Ewan Brown, Alan Christie, Sally McCormack, Mark Stares
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionImmune checkpoint inhibitors are the mainstay of treatment in patients with unresectable or metastatic melanoma. Combination immunotherapy with ipilimumab and nivolumab has shown to improve survival outcomes as compared to single agent im
Externí odkaz:
https://doaj.org/article/a8034d57ca354d9ab31f1ce0bc27f719
Autor:
Mark Stares, Vishwani Chauhan, Jigi Moudgil‐Joshi, Qiu G. Kong, Jahangeer Malik, Aravindhan Sundaramurthy, Tony Elliott, Edward Mains, Steve Leung, Alexander Laird, Stefan N. Symeonides
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 5255-5264 (2023)
Abstract A subset of patients with metastatic renal cell carcinoma (mRCC) follow an indolent disease course and may benefit from initial active surveillance (AS). However, selecting patients suitable for this approach is challenging. To investigate t
Externí odkaz:
https://doaj.org/article/94ac9f1ec66e4032b75c9c21bb4569d2
Autor:
Mark Stares, Amanda Swan, Kirsten Cumming, Tze-En Ding, James Leach, Cory Stratton, Findlay Thomson, Colin Barrie, Kirsty MacLennan, Sorcha Campbell, Tamasin Evans, Aisha Tufail, Stephen Harrow, Melanie MacKean, Iain Phillips
Publikováno v:
Frontiers in Nutrition, Vol 8 (2021)
Introduction: Despite significant advances in systemic anticancer therapy (SACT) for non-small cell lung cancer (NSCLC), many patients still fail to respond to treatment or develop treatment resistance. Albumin, a biomarker of systemic inflammation a
Externí odkaz:
https://doaj.org/article/207d54c6c7194b8f83f5f44fc9aad494
Publikováno v:
Frontiers in Bioscience-Landmark, Vol 27, Iss 4, p 129 (2022)
Lung cancer is the commonest malignancy worldwide and the leading cause of cancer death. Half of patients with lung cancer present with advanced disease. The number of systemic therapies including immunotherapy and targeted treatment are rapidly incr
Externí odkaz:
https://doaj.org/article/795b9c7f3de245d5a4e27917a2bec09b
Autor:
Dana Gebhart, Stephen Lok, Simon Clare, Myreen Tomas, Mark Stares, Dean Scholl, Curtis J. Donskey, Trevor D. Lawley, Gregory R. Govoni
Publikováno v:
mBio, Vol 6, Iss 2 (2015)
ABSTRACT Clostridium difficile is a leading cause of nosocomial infections worldwide and has become an urgent public health threat requiring immediate attention. Epidemic lineages of the BI/NAP1/027 strain type have emerged and spread through health
Externí odkaz:
https://doaj.org/article/56d6053b8e4743aea292009135fb17f2
Autor:
Iain Phillips, Mark Stares
Publikováno v:
Annals of Palliative Medicine. 12:262-264
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb0333615bec17d727e1d093f91e929c
https://doi.org/10.21037/apm-22-1416
https://doi.org/10.21037/apm-22-1416
Autor:
Marjory MacLennan, Karin Purshouse, Sally Clive, Mark Stares, C. Barrie, Rachel Haigh, Rebekah Patton, Aoife Gatenby, Jo McGinty, Jenny Irvine, Alan Christie, Gillian Knowles
Publikováno v:
British Journal of Cancer
Stares, M, Purshouse, K, Knowles, G, Haigh, R, Irvine, J, Gatenby, A, Patton, R, Mcginty, J, Christie, A, Maclennan, M, Barrie, C & Clive, S 2021, ' Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis ', British Journal of Cancer . https://doi.org/10.1038/s41416-021-01544-1
Stares, M, Purshouse, K, Knowles, G, Haigh, R, Irvine, J, Gatenby, A, Patton, R, Mcginty, J, Christie, A, Maclennan, M, Barrie, C & Clive, S 2021, ' Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis ', British Journal of Cancer . https://doi.org/10.1038/s41416-021-01544-1
Background In the United Kingdom, national guidance published in 2010 recommended the establishment of specialist teams to improve clinical pathways for patients presenting with malignancies of undefined primary origin (MUO) and cancer of unknown pri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::777959296c52003605364f57ec5c03bc
http://europepmc.org/articles/PMC8608886
http://europepmc.org/articles/PMC8608886
Autor:
Mark Stares, Vishwani Chauhan, Jigi Moudgil‐Joshi, Qiu G. Kong, Jahangeer Malik, Aravindhan Sundaramurthy, Tony Elliott, Edward Mains, Steve Leung, Alexander Laird, Stefan N. Symeonides
Publikováno v:
Stares, M, Chauhan, V, Moudgil-joshi, J, Kong, Q G, Malik, J, Sundaramurthy, A, Elliott, T, Mains, E, Leung, S, Laird, A & Symeonides, S N 2022, ' Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre ', Cancer Medicine . https://doi.org/10.1002/cam4.5330, https://doi.org/10.1002/cam4.5330
A subset of patients with metastatic renal cell carcinoma (mRCC) follow an indolent disease course and may benefit from initial active surveillance (AS). However, selecting patients suitable for this approach is challenging. To investigate this we so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbac32be05310c5c8233ce73406f9c76
https://hdl.handle.net/20.500.11820/0e03d910-e14e-42ea-860b-b57e25a2500c
https://hdl.handle.net/20.500.11820/0e03d910-e14e-42ea-860b-b57e25a2500c
Autor:
Sonam Ansel, Mark Stares, Robert J. Jones, Stefan N. Symeonides, Laura Manson, Anirban Ray-Chaudhuri, Manreet Randhawa, Sarah Slater, Abeera Devasar, Jahangeer Malik, Aravindhan Sundaramurthy, Tony Elliott, Balaji Venugopal
Publikováno v:
Journal of Clinical Oncology. 41:645-645
645 Background: The Keynote 426 trial demonstrated 3-weekly pembrolizumab 200mg (pem3w) plus axi twice daily is effective in aRCC. We previously reported real-world experience of pem6w + axi demonstrating a comparable safety profile to pem3w + axi re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::126ef949b3c0c67ea6dda9d144de41b2
https://doi.org/10.1200/jco.2023.41.6_suppl.645
https://doi.org/10.1200/jco.2023.41.6_suppl.645